[Evaluation of transit in vivo dosimetry using portal imaging and comparison with measurements using diodes.]

CONCLUSION: The performance of EPIgray(®) in in vivo dosimetry is consistent with the recommendations of the European Society for Radiotherapy and Oncology (ESTRO) and equivalent to semiconductor diodes for 3D-CRT. It also allows adequate control for IMRT, which is technically difficult to perform with the diodes. PMID: 24792230 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24792230?dopt=Abstract

Source: Cancer Radiotherapie - April 29, 2014 Category: Cancer & Oncology Authors: Royer P, Marchesi V, Rousseau V, Buchheit I, Wolf D, Peiffert D, Noël A Tags: Cancer Radiother Source Type: research